Search Results - "SUH, Cheolwon"

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma by Younes, Anas, Sehn, Laurie H, Johnson, Peter, Zinzani, Pier Luigi, Hong, Xiaonan, Zhu, Jun, Patti, Caterina, Belada, David, Samoilova, Olga, Suh, Cheolwon, Leppä, Sirpa, Rai, Shinya, Turgut, Mehmet, Jurczak, Wojciech, Cheung, Matthew C, Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Dührsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram, Carey, Jodi, Liu, Grace, Shreeve, S Martin, Sun, Steven, Zhuang, Sen Hong, Vermeulen, Jessica, Staudt, Louis M, Wilson, Wyndham

“…Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and…”
Get full text

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study by YAMAGUCHI, Motoko, KWONG, Yok-Lam, SUZUMIYA, Junji, KODAMA, Takao, KIMURA, Hiroshi, HYO, Rie, NAKAMURA, Shigeo, OSHIMI, Kazuo, SUZUKI, Ritsuro, WON SEOG KIM, MAEDA, Yoshinobu, HASHIMOTO, Chizuko, SUH, Cheolwon, IZUTSU, Koji, ISHIDA, Fumihiro, ISOBE, Yasushi, SUEOKA, Eisaburo

“…To explore a more effective treatment for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKL), we…”
Get full text

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung by Han, Ji-Youn, Park, Keunchil, Kim, Sang-We, Lee, Dae Ho, Kim, Hyae Young, Kim, Heung Tae, Ahn, Myung Ju, Yun, Tak, Ahn, Jin Seok, Suh, Cheolwon, Lee, Jung-Shin, Yoon, Sung Jin, Han, Jong Hee, Lee, Jae Won, Jo, Sook Jung, Lee, Jin Soo

“…Gefitinib has shown high response rate and improved progression-free survival (PFS) in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of…”
Get full text

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis by Kim, Seok Jin, Prof, Yoon, Dok Hyun, MD, Jaccard, Arnaud, MD, Chng, Wee Joo, MD, Lim, Soon Thye, MD, Hong, Huangming, MD, Park, Yong, MD, Chang, Kian Meng, MD, Maeda, Yoshinobu, MD, Ishida, Fumihiro, Prof, Shin, Dong-Yeop, MD, Kim, Jin Seok, MD, Jeong, Seong Hyun, MD, Yang, Deok-Hwan, MD, Jo, Jae-Cheol, MD, Lee, Gyeong-Won, MD, Choi, Chul Won, Prof, Lee, Won-Sik, MD, Chen, Tsai-Yun, MD, Kim, Kiyeun, Jung, Sin-Ho, PhD, Murayama, Tohru, MD, Oki, Yasuhiro, MD, Advani, Ranjana, MD, d'Amore, Francesco, Prof, Schmitz, Norbert, Prof, Suh, Cheolwon, Prof, Suzuki, Ritsuro, MD, Kwong, Yok Lam, Prof, Lin, Tong-Yu, MD, Kim, Won Seog, Prof

“…Summary Background The clinical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has improved substantially as a result of new treatment strategies…”
Get full text

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Ohmachi, Ken, Niitsu, Nozomi, Uchida, Toshiki, Kim, Seok Jin, Ando, Kiyoshi, Takahashi, Naoki, Takahashi, Naoto, Uike, Naokuni, Eom, Hyeon Seok, Chae, Yee Soo, Terauchi, Takashi, Tateishi, Ukihide, Tatsumi, Mitsuaki, Kim, Won Seog, Tobinai, Kensei, Suh, Cheolwon, Ogura, Michinori

“…Effective and less aggressive therapies are required for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for or…”
Get full text

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN) by Liu, Jin, Hu, Xiaoxia, Jia, Yanchun, Lu, Jin, Lee, Jae Hoon, Kim, Kihyun, Chen, Wenming, Liu, Aijun, Liu, Yang, Chen, Qi, Zhang, Chunyang, Suh, Cheolwon, Kim, Min Kyoung, Zhou, Fan, Chng, Wee Joo, Kumar, Shaji K., Durie, Brian, Hou, Jian, Fu, Weijun, Du, Juan

Get full text

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial by Yoo, Kwai Han, Lee, Hyewon, Suh, Cheolwon

“…Lymphomas are a heterogeneous group of disease entities with well-defined clinical, morphological, immunophenotypic, and cytogenetic characteristics. Moreover,…”
Get full text

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma by Kim, Jwa Hoon, Cho, Hyungwoo, Sung, Heungsup, Jung, Ah Ra, Lee, Yoon Sei, Lee, Sang-wook, Ryu, Jin-Sook, Chae, Eun Jin, Kim, Kyoung Won, Huh, Jooryung, Park, Chan-Sik, Yoon, Dok Hyun, Suh, Cheolwon

“…The role of the Epstein-Barr virus (EBV) status in the blood for predicting survival in post-transplantation lymphoproliferative disorders–diffuse large B-cell…”
Get full text

Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study by Kim, Seok Jin, Kim, Kihyun, Kim, Byung Soo, Kim, Chul Yong, Suh, Cheolwon, Huh, Jooryung, Lee, Sang-Wook, Kim, Jin Seok, Cho, Jaeho, Lee, Gyeong-Won, Kang, Ki Mun, Eom, Hyeon Seok, Pyo, Hong Ryull, Ahn, Yong Chan, Ko, Young Hyeh, Kim, Won Seog

“…On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of…”
Get full text

Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis by Lee, Kyoungmin, Yoon, Dok Hyun, Hong, Jung Yong, Kim, Shin, Kang, Eun Hee, Huh, Jooryung, Park, Chan-Sik, Lee, Sang Wook, Suh, Cheolwon

“…We evaluated the efficacy of systemic high-dose methotrexate (HD-MTX) for CNS prophylaxis in a prospectively recruited cohort of DLBCL patients at high risk of…”
Get full text

BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis by Roh, Jin, Cho, Hyungwoo, Pak, Hyo-Kyung, Lee, Yoon Sei, Lee, Sang-wook, Ryu, Jin-Sook, Chae, Eun Jin, Kim, Kyung Won, Huh, Jooryung, Choi, Yoon Seok, Jeong, Seong Hyun, Suh, Cheolwon, Yoon, Dok Hyun, Park, Chan-Sik

“…Overexpression of the BCL2 protein has been reported as a poor prognostic factor for diffuse large B-cell lymphoma (DLBCL). However, there are currently no…”
Get full text

Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma by Choi, Yun Jung, Kim, Dong Ha, Yoon, Dok Hyun, Suh, Cheolwon, Choi, Chang-Min, Lee, Jae Cheol, Hong, Jung Yong, Rho, Jin Kyung

“…Mantle cell lymphoma (MCL) is typically an aggressive and rare form of non-Hodgkin lymphoma (NHL) with a poor prognosis despite recent advances in…”
Get full text

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy by Lee, Dae Ho, Park, Keunchil, Kim, Joo Hang, Lee, Jong-Seok, Shin, Sang Won, Kang, Jin-Hyoung, Ahn, Myung-Ju, Ahn, Jin Seok, Suh, Cheolwon, Kim, Sang-We

“…Purpose: The ISTANA (IRESSA as Second-line Therapy in Advanced NSCLC—KoreA) study compared gefitinib with docetaxel in patients with advanced or metastatic…”
Get full text

CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma by Koh, Young Wha, Park, Chan-Sik, Yoon, Dok Hyun, Suh, Cheolwon, Huh, Jooryung

“…Recent studies have reported the prognostic value of tissue-associated magrophages (TAMs) in classical Hodgkin lymphoma (cHL). In addition, TAMs are implicated…”
Get full text

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group by Kim, Seok Jin, Hsu, Chiun, Song, Yu-Qin, Tay, Kevin, Hong, Xiao-Nan, Cao, Junning, Kim, Jin Seok, Eom, Hyeon Seok, Lee, Joon Hyeok, Zhu, Jun, Chang, Kian-Meng, Reksodiputro, Arry Harryanto, Tan, Daryl, Goh, Yeow Tee, Lee, Jejung, Intragumtornchai, Tanin, Chng, Wee-Joo, Cheng, Ann-Lii, Lim, Soon Thye, Suh, Cheolwon, Kwong, Yok-Lam, Kim, Won Seog

“…Abstract Background Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and…”
Get full text

Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities by Van Slambrouck, Charles, Huh, Jooryung, Suh, Cheolwon, Song, Joo Y., Menon, Madhu P., Sohani, Aliyah R., Duffield, Amy S., Goldberg, Reva C., Dama, Paola, Kiyotani, Kazuma, Godfrey, James, Fitzpatrick, Carrie, Kline, Justin, Smith, Sonali M., Jaffe, Elaine S., Hartmann, Sylvia, Venkataraman, Girish

“…Although the distinction of classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma using morphology and immunostains is…”
Get full text

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma by Kim, Seok Jin, Yoon, Dok Hyun, Kang, Hye Jin, Hong, Jung Yong, Lee, Ho Sup, Oh, Sung Yong, Shin, Ho-Jin, Kong, Jee Hyun, Yi, Jun Ho, Sakamoto, Kana, Ko, Young Hyeh, Huh, Jooryung, Lee, Seung-Sook, Takeuchi, Kengo, Shin, Dong-Yeop, Suh, Cheolwon, Kim, Won Seog

“…The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based…”
Get full text

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study by Kim, Won Seog, Oki, Yasuhiro, Kim, Seok Jin, Yoon, Sang Eun, Ardeshna, Kirit M., Lin, Yi, Ruan, Jia, Porcu, Pierluigi, Brammer, Jonathan E., Jacobsen, Eric D., Yoon, Dok Hyun, Suh, Cheolwon, Suarez, Felipe, Radford, John, Budde, Lihua E., Kim, Jin Seok, Bachy, Emmanuel, Lee, Hun Ju, Bollard, Catherine M., Jaccard, Arnaud, Kang, Hye Jin, Inman, Shannon, Murray, Maryann, Combs, Katherin E., Lee, Daniel Y., Advani, Ranjana, Gunter, Kurt C., Rooney, Cliona M., Heslop, Helen E.

“…We conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who…”
Get full text

Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study by LEE, Jeeyun, SUH, Cheolwon, HYO JIN KIM, SOON IL LEE, JUNG HAN KIM, PARK, Jinny, SEOK JOONG OH, KIM, Kihyun, JUNG, Chulwon, PARK, Keunchil, WON SEOG KIM, YEON HEE PARK, KO, Young H, SOO MEE BANG, JAE HOON LEE, DAE HO LEE, HUH, Jooryung, SUNG YONG OH, KWON, Hyuk-Chan

“…Patients with natural killer T (NK/T) -cell lymphomas have poor survival outcome, and for this condition there is no optimal therapy. The purpose of this study…”
Get full text

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis by Yoon, Sang Eun, Kim, Seok Jin, Yoon, Dok Hyun, Koh, Youngil, Mun, Yeung-Chul, Do, Young Rok, Choi, Yoon Seok, Yang, Deok Hwan, Kim, Min Kyoung, Lee, Gyeong-Won, Suh, Cheolwon, Ko, Young Hyeh, Kim, Won Seog

“…Epstein-Barr virus (EBV) positivity in diffuse large B cell lymphoma (DLBCL) provokes a critical oncogenic mechanism to activate intracellular signaling by…”
Get full text